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expression of TGF-RI in HCT116 cells. Addition of SB431542, a selective
inhibitor of TGF-RI, suppressed p53 elevation despite of TGF-1 suppression.
Consistently, suppression of TGF-RI inhibited p53 elevation and cell apoptosis
when expression of TGF-1 was suppressed in HCT116.
Conclusion: These results indicate that in TGF-RII-dysfunctional colorectal
cancer cells, endogenous TGF-1 has the potential to suppress p53 expression
via reduced TGF-RI expression, leading to resistance to apoptosis.
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Introduction: Serrated lesions of the colon comprise of a group of heterogeneous
lesions with distinct histological features. The large serrated polyps, in particular,
are associated with advanced colonic neoplasia and possibly higher risk of
colorectal cancer.1,2 However, there is a paucity of data on the optimal surveil-
lance interval for patients with different serrated lesions of the colon.
Aims & Methods:We aim to determine the polyp and adenoma detection rate on
surveillance colonoscopy in patients with different serrated lesions.
We identified patients who were diagnosed to have serrated lesions during
colonoscopy in our hospital between January 2008 and June 2011. Patients
with concurrent or past history of colorectal cancer were excluded. Patients
were categorized according to their baseline lesions: serrated adenoma (SA),
large (10mm) serrated polyps (LSP) and medium-sized (5-9mm) hyperplastic
polyps (MHP) without concomitant or past history of adenoma. Patients with
SA and LSP (SAþLSP group) were grouped together for analysis because of the
small number of patients in these groups. The proportion of patients and the time
to recurrent colonic polyps/adenoma on surveillance colonoscopy between the
two groups (SAþLSP vs MHP) were compared.
Results: 98 patients (24 SA, 9 LSP and 65 MHP) were included for analysis.
Surveillance colonoscopy was completed in 65 (66.4%) patients (20 SA, 7 LSP
and 38 MHP) with a total of 75 colonoscopy performed. The median age of the
patient in the SAþLSP group was significantly older than the MHP group (64.3
years, range 34-86 vs 55.8 years, range: 26-89; p¼ 0.023). The median time of
surveillance colonoscopy was 40.7 and 44.3 months in SAþLSP group and
MHP group respectively (p¼ 0.332). The proportions of patients with recurrent
colonic polyps (including serrated lesions and adenoma) on surveillance colono-
scopy were 63.0% and 36.8%, respectively (SAþLSP group vs MHP group)
(p¼ 0.038). There was also a significant difference on the time to polyps recur-
rence between the two group, with a lower rate in the MHP group (Log Rank;
P¼ 0.006). The adenoma detection rate on surveillance colonoscopy for
SAþLSP group and MHP group were however comparable (29.6% and
28.9%; p¼ 0.952). Amongst those who have recurrent polyps, 41.2% and
35.7% of patients developed serrated lesions in SAþLSP group and MHP
group respectively.
Conclusion: Patients with baseline SA and LSP have a significantly higher polyp
recurrence rate on surveillance colonoscopy. However, the adenoma detection
rate on surveillance colonoscopy was similar. These findings provide new data
when deciding on the optimal screening interval for patients with different base-
line serrated lesions.
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Introduction: Prokineticin-1 (PROK1) is thought to be involved with cell invasion
through the intermediary of prokineticin receptor 2 (PK-R2), that is one of the
Prokineticin-1 receptors. We report a function via PROK1-PK-R2 signaling in
vitro.
Aims & Methods: 1: Four colon cancer cell lines (DLD1, HCT116, SW620 and
HT29) were analyzed for PROK1 and PK-R2 protein expressions. 2: Two colon
cancer cell lines (DLD1 and HT116) stimulated with PROK1 protein, were
observed for 24 hours using ‘‘Olympus Fluoview 10i-w’’, for the presence of
change in cell movement. Furthermore, we measured the moving distance of
five cells in non-stimulated group and PROK1 stimulated group, compared
using the U test of Mann-Whitney. 3: The expression of PROK1 and PK-R2
protein was assessed in 325 colorectal cancer tissues by immunohistochemical
staining using anti-PROK1 antibody and anti-PK-R2 antibody. We investigated
the relation between PROK1 and PK-R2 expression and clinicopathological
factor. The association of PROK1 and PK-R2 expression with serosal invasion,
lymphatic invasion, venous invasion, lymph node metastasis, peritoneal metas-
tasis, and hematogenous metastasis was assessed by cross-tabulation, and statis-
tical significance was determined by the c2 test. Life-table analysis was performed
using Kaplan-Meier technique and outcomes from different groups of patients
were compared by the log rank test.
Results: 1: The expression of PROK1 and PK-R2 protein was detected in four
colon cancer cell lines. 2: The PROK1 stimulated group, compared to non-sti-
mulated group is a highly deformation of cells, and observed increased motility.
The average of the moving distance of the cells of DLD1 was 380.96 pixel in non-
stimulated group, in PROK1 stimulated group was 581.50 pixel. The average of
the moving distance of the cells of HCT116 was 286.29 pixel in non-stimulated
group, in PROK1 stimulated group was 400.90 pixel. Both cell lines showed a
significant extension of the moving distance of the cells in PROK1 stimulated
group. 3: Group1, positive both PROK1 and PK-R2, was 117 cases. Group2,
positive either PROK1 or PK-R2, but not both, was 109 cases. Group3, negative
both PROK1 and PK-R2, was 99 cases. According to the clinicopathological
examinations, the frequency of Group1 was significantly higher in cases with
lymphatic invasion, venous invasion, lymph node metastasis and hematogenous
metastasis. The prognosis for patients with Group1 were significantly worse than
the other groups.
Conclusion: Colon cancer cell lines stimulated with PROK1 protein, showed
enhancement of moving distance and deformation and motility of cells.
Signaling cascade thought PROK1/PK-R2 was suggested likely to be involved
in metastasis, especially cell invasion.
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Introduction: Serrated polyps comprise a heterogeneous group of lesions. The
reliable classification and their molecular profile are important to implement a
surveillance and screening approach.
Aims & Methods: We aimed to study BRAF and KRAS mutations and CpG
island methylator phenotype (CIMP) in the DNA of polyps in order to determine
molecular and histological differences and the prognostic value of these markers
in patients with serrated polyps. We performed a retrospective study with
patients recruited between 2007and 2009 with at least one surveillance colono-
scopy. A total of 994 polyps from 313 patients were collected for histological and
molecular analysis. We analyzed KRAS and BRAF mutations in the DNA of all
these polyps, and CIMP in 404 polyps from 103 patients. Mutation analysis for
KRAS (codons 12 and 13) was performed by DNA sequencing and BRAF
mutation (V600E) using allelic discrimination. CIMP was examined by MS-
MLPA, considering CIMP-positive when 5 out of 8 markers were methylated.
Results: Adenomas were the main lesion (68%, n=676), being 0.8% of them
mutated for BRAF, 11% for KRAS and 1.1% CIMP-positive. A total of 318
(32%) polyps were classified as serrated lesions: 265 (83.3%) were hyperplastic
polyps (HPs), 47 (14.8%) sessile serrated polyps (SSP) and 6 (1.9%) traditional
serrated adenomas (TSA). Of the serrated polyps, 39.7% of them showed BRAF
mutation, 20.3% KRAS mutation and 12.8% CIMP. Considering only serrated
polyps, we found BRAF mutation in 39.4% of HPs and in 40.8% of SSP and
KRAS mutations in 18.7% of HP and in 28.6% of SSP. There were no differ-
ences in the morphology, size and location of the serrated polyps depending on
the BRAF mutational status, while KRAS mutation was predominantly present
in rectum-sigmoid (p¼ 0.014). Serrated polyps were found in 104 patients at
baseline colonoscopy. The mutational status of BRAF did not predict the finding
of advanced adenomas or serrated lesions at follow-up. However the presence of
somatic mutations in KRAS in serrated polyps at baseline predicts advanced
lesions at follow-up. Patients with somatic BRAF mutation in polyps at baseline
do not show a higher proportion of advanced adenomas or large (4 1cm) or
proximal serrated polyps at follow-up (BRAF mutation: 34.5% vs no-BRAF
mutation 45.9%; p¼ 0.35). Regarding KRAS, there is a higher proportion of
advanced adenomas or advanced serrated polyps when serrated polyps at base-
line showed KRAS mutation (60.9% vs 30.2%; p¼ 0.016).
Conclusion:We found a low frequency of somatic BRAF or KRAS mutations in
serrated polyps. The presence of BRAF or KRAS mutation was not associated
with location, size or histology in serrated polyps. Patients with KRAS mutations
in serrated polyps show a higher risk of new advanced lesions in follow-up
colonoscopies.
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Introduction: Colorectal polyps with advanced pathology (adenoma with high-
grade dysplasia; HGD or intramucosal cancer) are considered to be precursor
lesions developing into invasive cancer. In the present study we aimed to evaluate
the relationship between the distributions of colorectal polyps with advanced
patholgy and those of invasive cancers with a special attention to proximal
location.
Aims & Methods: The study included 1064 patients (mean age 66.1þ-10.2yr,
M:F= 2.07:1) having colorectal polyps with advanced histology which were
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